Search results: (10000)
News How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients
Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They affect both specific and nonspecific immunity and are classified accordingly. The care for patients with antibody production disorders and hereditary angioedema (HAE) is economically the most demanding and relatively specific. Can a specialized registry help improve this care?
News INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
MUDr. Stanislav John, Ph.D.,
Clinic of Oncology and Radiotherapy, Faculty of Medicine, Charles University and University Hospital Hradec Králové
News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
News DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy
Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might offer additional benefits to patients apart from effective and safe glycemic control.
News Chemotherapy as a Risk Factor for Severe COVID-19 Course?
During the coronavirus pandemic, patients with malignant neoplastic diseases are considered an at-risk group. Whether chemotherapy is a risk factor for a more severe course of COVID-19 was the subject of the study presented below.
News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice
The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’
The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.
News Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?
News Current Findings on Fixed Combination Aclidinium/Formoterol in COPD Therapy
The fixed inhalation combination of aclidinium/formoterol represents a combination of a long-acting anticholinergic (LAMA) and a long-acting β2-mimetic (LABA) used for maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Below, we summarize the current findings on the efficacy and safety of this dual bronchodilation therapy.
News Morning Myopic Shift and Glare in Patients with Advanced Fuchs Endothelial Corneal Dystrophy
A newly published study by a German team analyzes the morning and afternoon differences in various parameters in patients with Fuchs endothelial corneal dystrophy to determine which of them contribute to subjective visual difficulties in the morning.
News News in the Treatment of Allergic Rhinitis
According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which negatively affects the quality of daily life. Below, we summarize the new recommendations from ARIA (Allergic Rhinitis and its Impact on Asthma) from 2019 regarding the treatment of this condition and highlight a new therapeutic option offered by the fixed combination of mometasone furoate with olopatadine hydrochloride.
News Principle of Slowed Wound Healing Due to Stress Revealed
There is no doubt that psychological stress significantly slows down the process of healing wounds. The principle of how this phenomenon occurs, however, has remained unexplained. Swiss scientists focused on macrophages. Their function is to remove pathogens from the healing wound.
News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity
A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.
News Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk of intracranial bleeding. Prophylactic and therapeutic interventions for blood clotting are necessary for cancer patients in indicated cases. But what about the risk of bleeding in patients with CNS malignancies?
News Contact Dermatitis in Patients with Venous Ulcers – and How to Prevent It?
The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.
News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma – A Case Study
We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.
News Li-Fraumeni Syndrome – Indication for Testing and Recommended Surveillance
A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition to the occurrence of malignant tumors, such as pediatric malignancies, breast cancer, bone sarcomas, and others. We bring a summary of indications for testing the pathogenic variant of the TP53 gene according to the recommendations of the National Comprehensive Cancer Network (NCCN) and the surveillance program for carriers of this variant according to the consensus of the current recommendations of the European, American, Japanese, and Australian scientific societies compared to the recommendations of the Czech Oncology Society ČLS JEP.
News Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia
Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.
News Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2, increase in Th17 cells, and conversely a decrease in T-regulatory lymphocytes (Tregs). One treatment option is the use of thrombopoietin receptor agonists (TPO-RA), which primarily increase platelet production. Recently, attention has also been focused on their potential immunomodulatory effects and protolerogenic effect associated with Tregs activation, which was the subject of the Swiss iROM study.
News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients
Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.
News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.